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CardiomyocyteWepreviously identiﬁed peptide Lv, a novel bioactive peptide that enhances the activity of L-type voltage-gated cal-
cium channels (L-VGCCs) in cone photoreceptors. In this study, we veriﬁed that peptide Lv was able to augment L-
VGCC currents in cardiomyocytes, as well as promote proliferation of endothelial cells. We used a proteomics ap-
proach to determine the speciﬁc receptors and binding partners of peptide Lv and found that vascular endothelial
growth factor receptor 2 (VEGFR2) interacted with peptide Lv. Peptide Lv treatment in embryonic cardiomyocytes
stimulated tyrosine autophosphorylation of VEGFR2 and activated its downstream signaling. Peptide Lv activitywas
blocked by DMH4, a VEGFR2 speciﬁc blocker, but not by SCH202676, an allosteric inhibitor of G protein-coupled re-
ceptors, suggesting that the activity of peptide Lv was mediated through VEGFR2 signaling. Inhibition of VEGFR ty-
rosine kinase or its downstream signaling molecules abolished the augmentation of L-VGCCs elicited by peptide Lv
in cardiomyocytes. In addition, peptide Lv promoted cell proliferation of cultured human endothelial cells. Calcium
entry through L-VGCCs is essential for excitation–contraction coupling in cardiomyocytes. Since peptide Lvwas able
to augment L-VGCCs through activation of VEGF signaling in cardiomyocytes and promote proliferation of endothe-
lial cells, peptide Lv may play an important role in regulating the cardiovascular system.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Peptide Lv, a novel bioactive peptide, was discovered by screening
the full length human and mouse cDNA databases with an improved
bioinformatics strategy modiﬁed from the Hidden Markov model [1].
“Peptide Lv” was named according to its ability to enhance L-type
voltage-gated calcium channel (L-VGCC) currents in retinal photorecep-
tors [1]. The genomic sequence of peptide Lv is embedded in themouse
E130203B14Rik gene (Gene ID: 320736), which is predicted to encode
a hypothetical immunoglobulin-like protein. The corresponding
gene in humans is known as the V-set and transmembrane domain-
containing 4 (VSTM4, also known as C10orf72; Gene ID: 196740),
which is located on chromosome 10 and may be associated with late-
onset Alzheimer's disease [2]. Chromosome 10 also contains genes
encoding chemokines, cadherins, excision repair proteins, early
growth response factors, and ﬁbroblast growth receptors.
Mutations of genes on chromosome 10 are associated with Charcot–
Marie–Tooth disease, Jackson–Weiss syndrome, Usher syndrome,
nonsyndromatic deafness, Wolman's syndrome, Cowden syndrome,tegrative Biosciences, College of
University, 4458 TAMU, College
: +1 979 847 8981.multiple endocrine neoplasia type 2, and porphyria [3–9]. Downregula-
tion of C10orf72 in cultured breast cancer cells using RNAi enhances the
sensitivity to tamoxifen and suppresses the growth of these cells [10].
Even though the identities of the biological proteins translated from
E130203B14Rik/C10orf72 are not completely known, based on the
evidence mentioned above, identiﬁcation and characterization of
proteins translated from this gene, including peptide Lv, will enable us
to fully understand the functions of this gene.
The main peptide Lv coding region contains 49 amino acids in mice
and 40 in human, which is conserved across human, mouse, rat, and
chicken [1]. The peptide LvmRNA is widely expressed in various organs
including the lung, spleen, intestine, retina, and various regions in the
brain. However, the binding partners and receptors of peptide Lv are
unknown, which completely cloud the physiological functions of pep-
tide Lv. Since the brain expresses peptide Lv, in this study we applied
a proteomics approach using a mouse whole brain preparation, and
identiﬁed that vascular endothelial growth factor receptor 2 (VEGFR2)
is a binding partner of peptide Lv. VEGFR2 (KDR/FLK-1) belongs to a
tyrosine kinase receptor family that is subjected to autophosphorylation
of tyrosine residues after the receptor is activated via ligand binding
[11]. VEGFR signaling is essential for the development of the cardiovas-
cular system during embryonic stages, and it is critical for angiogenesis
and wound healing throughout adulthood [11]. There are four major
tyrosine autophosphorylation sites (951, 1054/1059, 1175, and 1212/
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phosphorylation sites may elicit different signaling pathways upon
activation, thus prompting different functions. Since VEGFR2 is impor-
tant in thedevelopingheart,we further veriﬁed the interaction between
peptide Lv and VEGFR2 in the embryonic chicken heart. In this report,
we examined the physiological effects of peptide Lv in embryonic
chicken cardiomyocytes and human endothelial cells and established
a potential functional link between peptide Lv and VEGFR2.
We previously showed that exogenous peptide Lv increases L-VGCC
currents in cultured retinal photoreceptors [1]. The augmentation of L-
VGCC currents is mainly through the increase of mRNA and protein
expressions of L-VGCCα1 subunits. The L-VGCCs are highly expressed
in the nervous and cardiovascular systems [12,13]. The voltage-
dependent calcium entry through L-VGCCs promotes various cellular
processes including regulating intracellular calcium homeostasis,
modulating activities of calcium-dependent enzymes, and further
regulating gene expressions [14]. In particular, L-VGCCs are essential
for neurotransmitter release from non-spiking neurons, such as retinal
photoreceptors and bipolar cells [15]. In cardiomyocytes, the L-VGCCs
contribute to the action potential and excitation–contraction coupling
[12,13], and dysregulation of L-VGCCs in the cardiovascular system
causes cardiac arrhythmias and heart failure [16,17]. Since L-VGCCs
are important for the function of cardiomyocytes, in this study we
further explored whether peptide Lv regulated cardiomyocyte physiol-
ogy and examined the signaling molecules that mediate the action of
peptide Lv.
2. Materials and methods
2.1. Chicken embryonic cardiomyocyte culture and peptide Lv treatment
All experimental procedures complied with the regulations of Texas
A&M University. Fertilized eggs (Gallus gallus, Single Comb White
Leghorns) were obtained from the Poultry Science Department, Texas
A&M University (College Station, TX, USA). All chicken embryos were
maintained at 39 °C ± 0.5 °C. Chicken hearts were harvested at embry-
onic day 12 (E12) and ventricular cardiomyocytes were dissociated and
cultured on poly-D-lysine/collagen double-coated dishes (for biochemi-
cal andmolecular biological assays) or coverslips (for electrophysiolog-
ical recordings) as described previously [18]. The culture medium
contained Dulbecco's modiﬁed Eagle's medium (DMEM; BioWhittaker,
Walkersville, MD, USA), 5% fetal bovine serum (FBS, HyClone, Logan,
UT, USA), 10% heat-inactivated horse serum (BioWhittaker), 2 mM
GlutaMax (Gibco/Invitrogen, Carlsbad, CA, USA), 50 U/ml penicillin
(Sigma, St. Louis, MO, USA), 50 μg/ml streptomycin (Sigma), and 5 μg/
ml retinol (Sigma). All cultures were maintained at 39 °C ± 0.5 °C
with 5% CO2. Cells were cultured for 2–3 days and subjected to
treatments with vehicle, peptide Lv, or pharmaceutical blockers prior
to Western blotting or electrophysiological recordings. SCH202676,
DMH4, PD98059, and chelerythrine chloride were purchased from
Tocris Bioscience (Minneapolis, MN, USA). Pertussis toxin (PTX) was
from Calbiochem/EMD (San Diego, CA, USA). The endogenous ligand
for VEGF receptor, VEGFa, and the VEGFa antibody were from Bioss
Antibodies (Woburn, MA, USA). Synthesized peptide Lv was obtained
from GenScript (Piscataway, NJ, USA) and dissolved in 40% acetic acid/
water to reach a stock concentration of 2 mg/ml.
2.2. Reverse transcription PCR (RT-PCR)
Total RNA from mouse eyes, spleen, intestine, lung, and heart were
isolated (Qiagen, Valencia, CA, USA). One step RT-PCR ampliﬁcation
(Applied Biosystems/Life Technologies, Grand Island, NY, USA) was
used for detection of peptide Lv precursor and GAPDH mRNA expres-
sion as described previously [1]. The primers for peptide Lv: sense prim-
er was 5′-GAATTCATGCGGCTCCTAGCGCTGGCGGCGG-3′; antisense
primer was 5′-CTCGAGCTACAGCTGGTTCTCCTCGAAGAGGA-3′. Formouse GAPDH, the forward primer was 5′-CATTGTGGAAGGGCTCAT
GACCA-3′, and reverse primer was 5′-TGGGATGACCTT GCCCACAGCC
TTG-3′.
2.3. Western blots and trichloroacetic acid (TCA) precipitation
Treated or control cells were washed and lysed in radioimmuno-
precipitation assay (RIPA) buffer, and proteins were denatured by
mixing with 2× Laemmli sample buffer for 5 min at 95 °C. Samples
were separated on 10% sodiumdodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) gels and transferred to nitrocellulose mem-
branes. The primary antibodies used in this study were pan L-VGCCα1
(Chemicon/Millipore, Temecula, CA, USA), ERK1/2 (Santa Cruz Bio-
chemicals, Santa Cruz, CA, USA), di-phosphorylated ERK1/2 (pERK1/2,
Sigma), actin (Cell Signaling Technology, Danvers, MA, USA), AKT (Cell
Signaling Technology), phosphorylated AKT at thr308 (pAKT308; Cell
Signaling Technology), phosphorylated PKC α/βII subunit (pPKC α/β;
Cell Signaling Technology), phosphorylated tyrosine (pTyr-100; Cell
Signaling Technology), VEGFR2 (Cell Signaling Technology), and phos-
phorylated VEGFR2 at tyr1054/1059 (pVEGFR2 at tyr1054/1059; Cell
Signaling Technology). Chickens appear to express a single form of
ERK (on the basis of molecular weight), so the antibodies against
ERK1/2 and pERK1/2 only label a single band on Western blots, while
both antibodies label two bands in samples prepared frommammalian
origins [19,20]. Blots were visualized by the appropriate secondary
antibodies and an ECL detection system (Pierce/Thermo Scientiﬁc,
Rockford, IL, USA). For TCA precipitation, 100% (g/ml) TCA was added
to each sample to achieve a ﬁnal concentration of 20%. The samples
were kept on ice for 4 h then the precipitate was collected by centrifu-
gation. Pellets were washed twice with acetone and completely air
dried before addition of SDS sample buffer.
2.4. Electrophysiological recordings and statistical analysis
Ventricular cardiomyocytes were cultured for two days. Whole-cell
patch-clamp recordings of L-VGCC currentswere carried out from spon-
taneously pulsing cardiomyocytes [21]. The external solution was
(in mM): 145 TEACl, 9 BaCl2, 0.5 MgCl2, 5.5 glucose, 0.1 NiCl2, and 5
HEPES, pH 7.4 with CsOH or TEAOH. The pipette solution was (in
mM): 125 Cs acetate, 20 CsCl, 3MgCl2, 10 EGTA, and 5HEPES, pH 7.4 ad-
justed with CsOH. Currents were recorded at room temperature using
an A-M Systems model 2400 patch-clamp ampliﬁer (Sequim, WA,
USA). Signals were low-pass ﬁltered at 2 kHz and digitized at 5 kHz
with Digidata 1440A interface and pCLAMP 10.0 software (Molecular
Devices, Sunnyvale, CA, USA). Cardiomyocytes were held at−40 mV,
and Ba2+ currents were recorded immediately after whole-cell patches
were formed by gentle suctions. Current–voltage (I–V) relationships
were elicited from a holding potential at−40 mV using 200 ms steps
(5 s between steps) over a range from−60 to+60mV in 10mV incre-
ments. The current densities were calculated by dividing the current
amplitudes (pA) by membrane capacitances (pF).
2.5. Co-immunoprecipitation and proteomics with mouse brains
Adultmousewhole brainswere collected and lysed in 8ml immuno-
precipitation buffer (Thermo Scientiﬁc) containing a protease inhibitor
cocktail (Sigma). The cell lysate was cleaned with 1 ml sepharose 4B
resin prior to incubationwith peptide Lv antibody conjugated sepharose
4B. 10 μg custom-made rabbit polyclonal antibody (Biomatik, Ontario,
Canada) was immobilized in 40 μl AminoLink Plus Coupling Resin by
following the manufacturer's protocol (Thermo Scientiﬁc). The lysate
and antibody were incubated for 5 h at 4 °C. The resins were washed
three times with immunoprecipitation buffer and twice with PBS.
Samples were resolved on 12% SDS-PAGE gels and stained with
Coomassie brilliant blue R-250. Four major bands ranging from 40 to
200 kD were carefully excised and subjected to in-gel digestion and
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mass spectrometry. Mass spectrometry and database analysis were
performed in the Laboratory of Biological Mass Spectrometry, Texas
A&M University.
2.6. Co-immunoprecipitation (co-IP)
Eight chicken embryonic hearts (E18) were collected and homoge-
nized in 4 ml of immunoprecipitation buffer (Thermo Scientiﬁc).
Samples were rotated at 4 °C for 2 h to solubilize membrane proteins.
Samples were then centrifuged to remove cell debris, and a small
portion of the supernatantwas taken for protein quantiﬁcation analyses
and for a SDS-PAGE gel subsequently stained with Coomassie brilliant
blue R-250. The rest of the supernatant was cleaned with Protein A-
agarose beads (GBiosciences, Maryland Heights, MO, USA) followed by
incubating the beads with10 μl of the antibody (anti-peptide Lv or
anti-VEGFR2) for 3 h. Because both anti-peptide Lv and anti-VEGFR2
antibodies were derived from the rabbit, we used rabbit IgG in our
study as our negative control. Any protein fractions that could co-IP
with rabbit IgG, as well as anti-peptide Lv or anti-VEGFR2 antibody,
would be considered to be non-speciﬁc protein targets of peptide Lv.
After incubation, 20 μl of Protein A-agarose was added to each tube
and incubated for another 1.5 h. The beads were collected, washed,
and processed for Western blotting analysis of peptide Lv and VEGFR2.
Western blots were visualized as described previously. For some IPs,
antibody preparatory and immunoprecipitation kits (Thermo Scientiﬁc)
were used to remove heavy and light chain interference. All co-IPs were
repeated three times.
2.7. Tetrazoliumdye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) colorimetric assay for cell proliferation
Human Umbilical Vein Endothelial Cells (HUVECs) were seeded onto
24-well plates in endothelial cell growth medium (Cell Application, San
Diego, CA, USA) and allowed to adhere overnight. The culture media
were exchanged to opti-MEM (Cell Application) for 45 min. Peptide Lv
(200 or 500 ng/ml)was added to the cells, and the cells were continuous-
ly incubated for another 48 h. Opti-MEMwith 20% FBS alone acted as the
negative control. Theproliferation ofHUVECswas determinedby theMTT
assay following the manufacturer's protocol (Life Technology). In brief,
cells were incubated with theMTT solution (1.2 mM ﬁnal concentration)
for 4 h at 37 °C. Then DMSO was added to a ﬁnal concentration of 50% in
order to break the plasmamembrane, and the absorbance at 540 nmwas
measured by a spectrophotometer.
2.8. Statistics
All data are presented asmean± standard error of themean (SEM).
Student's t-test or one-wayANOVA followed by Tukey's post hoc test for
unbalanced nwas used for statistical analyses. Throughout, p b 0.05was
regarded as signiﬁcant.
3. Results
3.1. Peptide Lv enhanced L-VGCC activities in time- and dose-dependent
manners in cardiomyocytes
Previously, we demonstrated that peptide Lv enhances the L-VGCC
currents in retinal photoreceptors in time- and dose-dependent fashions
[1]. Since the L-VGCCs are essential in the excitation–contraction coupling
of cardiomyocytes [12,13], we postulated that peptide Lv might also reg-
ulate the L-VGCCs in cardiomyocytes similar to its action in the photore-
ceptors. To test our hypothesis, cultured embryonic cardiomyocytes
were treated with a synthetic peptide Lv for 4 h at 500 ng/ml or
1000 ng/ml followed by the patch-clamp electrophysiological recordings
of L-VGCC currents. At 1000 ng/ml, peptide Lv elicited signiﬁcantly higherL-VGCC currents (Fig. 1A). Treatment with peptide Lv for only 30 or
60 min quickly elicited an increase of L-VGCC currents (Fig. 1B), which
was in part through an increase of protein expression of the pore-
forming L-VGCCα1 subunits (Fig. 1C). Since the mRNA of peptide Lv
was present in various tissues, including the heart (Fig. 1D), eye, and var-
ious brain areas [1], we next veriﬁed the existence of a functional peptide
Lv expressed endogenously. If a functional peptide Lv is expressed in the
heart, application of an antibody speciﬁcally against peptide Lv might af-
fect L-VGCCs by antagonizing the action of endogenous peptide Lv in em-
bryonic cardiomyocytes. Cultured embryonic cardiomyocytes were
treated with a speciﬁc antibody against peptide Lv for 18–22 h prior to
patch-clamp recordings. Cardiomyocytes treated with the anti-peptide
Lv antibody (α-peptide Lv) showed decreased L-VGCC currents, while
in contrast, cardiomyocytes treatedwith a denatured anti-peptide Lv an-
tibody did not have diminished L-VGCC currents (Fig. 1D). These results
demonstrated that exogenous peptide Lv augmented the L-VGCCs by en-
hancing the expression of L-VGCCα1 subunits, and blocking the endoge-
nous peptide Lv dampened the L-VGCC currents, hereafter indicating a
functional role of peptide Lv in cardiomyocytes during embryonic
development.
3.2. Identiﬁcation of VEGFR2 (KDR/FLK-1) as a binding partner for
peptide Lv
We utilized a proteomics approach to identify potential receptors or
binding partners in order to determine the underlyingmolecularmech-
anisms of peptide Lv on L-VGCCs in both photoreceptors and
cardiomyocytes. Since the mouse brain also expresses peptide Lv
abundantly [1] and yields more tissue than the heart, we used a
mouse whole brain preparation with co-immunoprecipitation (co-IP)
followed by a SDS-PAGE and mass spectrometry analysis to narrow
down the potential receptor candidates for peptide Lv. The co-IP
samples (using the anti-peptide Lv antibody) were resolved by SDS-
PAGE and visualized by Coomassie blue staining (Fig. 2A). There were
ﬁve major bands visible on the SDS-PAGE, but only the top four bands
with molecular weights ranging from 40 kD to 200 kD were excised
and subjected to MALDI-TOF MS analyses (Fig. 2A). The lowest band
was not selected for the MS analysis because this protein fraction was
also present in the co-IP with a rabbit IgG (as our control), indicating
that its interaction with anti-peptide Lv antibody was non-speciﬁc.
Hence, only the top four major bands were further subjected for the
MS-proteomics analyses. Excluding the cytoskeleton chaperone
proteins (myosin, clathrin heavy chain, and tubulin), there were three
potential receptor-like candidates, including KDR protein (VEGFR2/
KDR/FLK-1) (Access No. EDL37891), Fc receptor-like B (Access No.
NP_001025155), and vomeronasal type-1 receptor (Access No.
NP_035814). The vomeronasal type-1 receptor is a G-protein coupled
pheromone receptor mainly located in the olfactory bulb [22]. The Fc
receptor-like B is a member of the Fc receptor family that is involved
in phagocytosis, antibody-dependent cell cytotoxicity, and transcytosis
[23]. The KDR/FLK1 protein, also known as the vascular endothelial
growth factor receptor 2 (VEGFR2), belongs to the tyrosine kinase
(TK) receptor family [11]. Further proteomics analysis indicated that
VEGFR2 (KDR/FLK1) and vomeronasal type-1 receptor were the possi-
ble candidate receptors for peptide Lv. To determine which receptor
interacted with peptide Lv, we employed co-IP assays (Fig. 2B,
C) and found an interaction between peptide Lv and VEGFR2 in the
chick hearts. Using the anti-peptide Lv antibody, we were able to co-
immunoprecipitate a protein near 250 kD (*) from the E18 chicken
hearts that was detected with the anti-VEGFR2 antibody (Fig. 2B).
While we used the anti-VEGFR2 antibody to co-immunoprecipitate
proteins, a protein near 6 kD (#) was detected with the anti-peptide Lv
antibody (Fig. 2C). In both cases, we did not detect the presence of
VEGFR2 or peptide Lv using the rabbit IgG for co-IP (Fig. 2B and C). In
cultured cardiomyocytes, treatment with a selective VEGFR2 inhibitor,
DMH4 (5 μM) [24], was able to block the augmentation effect of peptide
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Fig. 1. Peptide Lv enhances L-VGCC currents and protein expression in cultured embryonic cardiomyocytes. (A) The augmentation of L-VGCC currents by peptide Lv was dose-dependent.
Cardiomyocytes were dissociated and cultured at E12, and L-VGCC currents were recorded at E14. Cultures were treated with 0, 500, and 1000 ng/ml of synthetic peptide Lv for 4 h prior
to electrophysiological recordings. There was a stepwise increase in the L-VGCC current densities with 1000 ng/ml peptide Lv being signiﬁcantly higher. (B) The effect of peptide Lv on L-
VGCCs in cardiomyocytes was time-dependent. Cardiomyocytes were treated with synthetic peptide Lv (500 ng/ml) for 0, 30, or 60 min prior to electrophysiological recordings.
(C) Treatment with synthetic peptide Lv (500 ng/ml) for 4 h in cultured cardiomyocytes (E12 + 2) elicited a signiﬁcant increase of L-VGCCα1 expression (1.98 ± 0.29 folds; * indicates a
signiﬁcant difference at p b 0.05). (D1) The mRNA of the precursor peptide of peptide Lv was detected in the mouse eye, spleen, intestine, lung, and heart. (D2 and D3) A speciﬁc antibody
against peptide Lv (α-peptide Lv) decreased L-VGCC currents. Cultureswere treatedwith peptide Lv antibody or heat-inactivated peptide Lv antibody (5 μg/ml; denatured antibody) for 24 h
prior to electrophysiological recordings. Treatmentwith thepeptide Lv speciﬁc antibody decreased themaximal current density of L-VGCCs compared to the L-VGCCs recorded from the con-
trol or cardiomyocytes treated with denatured antibody.
1157L. Shi et al. / Biochimica et Biophysica Acta 1853 (2015) 1154–1164Lv on L-VGCC currents (Fig. 3A), but DMH4 by itself did not affect the L-
VGCCs, indicating that the action of peptide Lv on L-VGCCs was in part
through the VEGFR2. Hence, VEGFR2 (KDR/FLK1) was a potential recep-
tor for peptide Lv.3.3. Peptide Lv stimulated VEGFR2 autophosphorylation in cardiomyocytes
Since VEGFR2 belongs to a tyrosine kinase receptor family that is
subjected to autophosphorylation of tyrosine residues after the receptor
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tential receptors for peptide Lv. Four major bands indicated by arrows with molecular
weights ranging from 40 to 200 kD were excised for MALDI-TOF analyses.
(B, C) Veriﬁcation of the interaction between peptide Lv and VEGFR2 was carried out in
chicken embryonic heart lysate using co-immunoprecipitation (co-IP). (B) Anti-peptide
Lv antibody was able to pull down VEGFR2 (*). (C) Likewise, anti-VEGFR2 antibody was
able to pull down peptide Lv (#). The rabbit IgG (rabbit Ig) was used as a control.
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Lv would elicit tyrosine phosphorylation of VEGFR2. Among the four
tyrosine phosphorylation sites on VEGFR2, tyr1054/1059 phosphoryla-
tion is required for maximal kinase activation and is considered a pre-
requisite for activating VEGFR2 signaling [25]. Because the amino acid
sequences near tyr1054/1059 of VEGFR2 are highly conserved across
the chicken,mouse, and human, the speciﬁc antibody against phosphor-
ylated VEGFR2 at tyr1054/1059 (pVEGFR2-tyr1054/1059) was used
to detect VEGFR2 autophosphorylation. We also used a p-tyr-100
antibody, an antibody used to detect phosphorylated tyrosine residues,
to verify the activation of tyrosine kinases. Cultured chicken embryonic
cardiomyocytes were treated with peptide Lv in the presence or
absence of DMH4. Peptide Lv elicited enhanced phosphorylation of
VEGFR2 (pVEGFR2-tyr1054/1059) and phosphorylated tyrosine, but
DMH4 blocked these effects (Fig. 3B). We also found that treatment
with peptide Lv was able to elicit tyrosine autophosphorylation of
VEGFR2 (pVEGFR2-tyr1054/1059) within 30 min, and this phosphory-
lation was time-dependent with a maximal activation at 2 h (Fig. 3C).
Hence, VEGFR2 was a candidate receptor for peptide Lv.
3.4. Peptide Lv activated downstream signaling molecules of VEGFR2 in
cardiomyocytes
Activation of VEGFR2 triggers several downstream signaling cascades,
including phosphoinositide phospholipase C (PLCγ), phosphoinositide 3-
kinase (PI3K), and mitogen-activated protein kinase (MAPK) and
extracellular signal-regulated kinase (ERK) pathways [26,27].Phosphoinositide phospholipase C (PLC) participates in phos-
phatidylinositol 4,5-bisphosphate (PIP2) metabolism and generates
inositol triphosphate (IP3) and diacylglycerol (DAG), in which DAG
further serves as an activator of protein kinase C (PKC) [28]. In both
porcine aortic endothelial cells and cultured cardiomyocytes, activa-
tion of VEGFR2 causes phosphorylation and activation of ERK1/2
[29]. Since PKC and ERK are downstream of VEGFR2, we next exam-
ined whether these signaling molecules would respond to peptide Lv
treatments. In cultured cardiomyocytes, treatment of peptide Lv for
4 h increased the phosphorylation levels of ERK (pERK) and PKC
(pPKCα/β, Fig. 4A and B). While the general G-protein coupled re-
ceptor (GPCR) inhibitor SCH202676 did not inhibit the effects of
peptide Lv on pERK and pPKCα/β, the VEGFR2 inhibitor DMH4 did
(Fig. 4B), indicating that peptide Lv was able to elicit activation/
phosphorylation of the downstream signaling targets of VEGFR2,
the ERK and PKC. Treatment with PD98059 (50 μM), an inhibitor of
MEK1 upstream of ERK, decreased the peptide Lv augmentation of
L-VGCC currents (Fig. 4C), as did the PKC inhibitor chelerythrine
(2 μM, Fig. 4D). Inhibition of PKC or MEK1-ERK signaling blocked
the effect of peptide Lv on L-VGCCs. Hence, the action of peptide Lv
on L-VGCC augmentation ﬁrst went through VEGFR2 binding,
which further activated downstream signaling, including PKC and
ERK.
3.5. The VEGF signaling pathway increases L-VGCC activities in the
cardiomyocytes
As demonstrated above, peptide Lv augmented L-VGCC activities
through the VEGFR2 signaling pathway in chicken cardiomyocytes
(Fig. 3A). While both VEGFR2 and VEGFa (an endogenous VEGFR2
agonist) are present in cultured embryonic or neonatal cardiomyocytes
[32], thus far, there is no report on the activation of VEGFR directly
eliciting an increase of L-VGCCs in cardiomyocytes. We found that
treatment with VEGFa (50 ng/ml) for 4 h signiﬁcantly increased L-VGCC
currents (Fig. 5A). Treatment with the VEGFR2 antagonist (DMH4,
5 μM) blocked the augmentation of L-VGCCs by VEGFa (Fig. 5A). Treat-
ment with a speciﬁc antibody against VEGFa (VEGF antibody) signiﬁ-
cantly decreased the L-VGCCs in cultured embryonic cardiomyocytes
(Fig. 5B), indicating that endogenous VEGF signaling was involved in
the regulation of L-VGCCs in embryonic cardiomyocytes. These data sup-
port the notion that activation of VEGFR2 can augment the L-VGCCs in
cardiomyocytes, which further conﬁrms that peptide Lvmimics endoge-
nous VEGF and increases L-VGCC currents in cardiomyocytes through ac-
tivation of VEGFR2 signaling.
3.6. Peptide Lv stimulated the VEGFR2 activation in the human umbilical
vein endothelial (HUVE) cells
Wealso tested the interaction between peptide Lv and VEGFR2 in cul-
tured human umbilical vein endothelial cells (HUVECs) to verify that the
action of peptide Lv to activate VEGFR2 was not solely in chicken
cardiomyocytes. We chose HUVECs due to the high expression of
VEGFR2 in vascular endothelial cells and the role of VEGFR2 signaling in
angiogenesis [11]. The VEGFR2 was co-immunoprecipitated with the
anti-peptide Lv antibody (α-peptide Lv) but not with the rabbit IgG
from cultured HUVECs (rabbit Ig; Fig. 6A), which was similar to the co-
IP result in embryonic chick hearts (Fig. 2). To further validate if peptide
Lv could also activate VEGFR2 (measured as pVEGFR2) in HUVECs as in
chicken cardiomyocytes (Figs. 3 and 4), cultured HUVECs were treated
with 500 ng/ml peptide Lv for 0, 30, or 60min before cellswere harvested
for Western immunoblotting. Antibodies against pVEGFR2 (tyr1054/
1059), total VEGFR2, total ERK1/2, andpERK1/2were used in theWestern
blots. Treatments with peptide Lv in cultured HUVECs increased both
pVEGFR2 and pERK1/2 levels (Fig. 6B). Therefore, peptide Lv was able to
activate VEGFR2 and its downstream signaling pathway in cultured
human endothelial cells, as well as in chicken cardiomyocytes.
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endothelial cells and thus promotes angiogenesis [11]. Mutations of
VEGFR2 result in deﬁcits in blood-island formation and angiogenesis,
which is lethal during embryonic development [33]. In response to
angiogenic stimuli, endothelial cells proliferate, migrate, and coalesce
to form a primitive vascular system and further recruit smooth muscle
cells to give rise to mature blood vessels [34,35]. Since peptide Lv acti-
vated VEGFR2 and its downstream signaling in both cardiomyocytes
and vascular endothelial cells, we postulated that peptide Lv might
enhance the transformation or production of embryonic endothelial
cells thus promoting angiogenesis. The HUVECs were treated with
peptide Lv (200 or 500 ng/ml) or vehicle for 48 h, and then subjected
to the tetrazolium dye (MTT) colorimetric assay to assess cell prolifera-
tion (Fig. 6C). The cells treated with peptide Lv (both at 200 and
500 ng/ml) had a signiﬁcant increase in the color absorbance at
540 nm indicating that there were more endothelial cells in the phase
of proliferation after treatments with peptide Lv.
4. Discussion
We previously identiﬁed peptide Lv, a novel putative peptide that
enhances L-VGCC activities in cone photoreceptors through increased
expressions of both mRNA and protein levels [1]. In this report, weidentiﬁed that VEGFR2 (KDR/FLK-1) was a potential receptor for
peptide Lv, which was an underlying mechanism for the augmentation
of L-VGCCs by peptide Lv in the cardiomyocytes. Peptide Lv was able to
activate the phosphorylation of VEGFR2 (KDR/FLK-1) and its down-
stream signaling, while inhibition of VEGFR2 (KDR/FLK-1) signaling
blocked the actions of peptide Lv. Our results suggest that peptide Lv
can serve as a novel activator of VEGFR2 through its augmentation of
L-VGCCs in cardiomyocytes and its action on promoting proliferation
of endothelial cells. Furthermore, peptide Lv might have angiogenic
properties and play a regulatory role in the cardiovascular system.
In the cardiovascular system, peptide hormones, such as somatostatin,
angiotensin II, and natriuretic peptides (BNP and CNP), are known to be
involved in the regulation of heart rate, cardiac contraction, and
development [36–38]. Several VEGF family members, including VEGFa,
VEGFb, VEGFc, VEGFd, platelet-derived growth factor (PDGF), and
placental growth factor (PLGF), can activate VEGFRs to regulate angiogen-
esis and lymphangiogenesis [11]. Even though we compared the amino
acid sequences of peptide Lv and the VEGF family, there is not much ho-
mology. Through I-TASSER [39],we obtained a predicted secondary struc-
ture for peptide Lv and found some similarities with VEGF members
(Fig. 7) [40]. Therefore, peptide Lv as a novel activator for VEGFR2 may
differ fromother VEGF familymembers interactingwithVEGFR2.Howev-
er,whether peptide Lv could have a synergistic or competitive actionwith
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1160 L. Shi et al. / Biochimica et Biophysica Acta 1853 (2015) 1154–1164VEGF family members in the cardiovascular system needs future investi-
gations. The mechanism by which peptide Lv interacts with VEGFR2 and
promotesVEGFR2dimerization [11] remains an interestingquestion to be
addressed through further studies. Activation of VEGFR2 signaling elicits a
rise of intracellular calcium concentration [30,31] through an increase of
the intracellular calcium store-related proteins or the conductance of
transient receptor potential (TRP) channels in various cell types
[41–43]. In cardiomyocytes, calcium inﬂux through L-VGCCs triggers cal-
cium release from intracellular calcium stores, activates Ca2+-dependent
kinases, and leads to excitation–contraction coupling [13]. The VEGF–PLCγ pathway is known to control cardiac contractility in the embryonic
heart [44]. Even thoughwe showed that peptide Lv increased L-VGCC cur-
rents and the expression of L-VGCCα1 subunits through the VEGFR2 sig-
naling pathway in cardiomyocytes, whether L-VGCCs are involved in the
VEGF-mediated calcium-induced intracellular calcium release needs fu-
ture investigation. We postulate that the peptide Lv augmentation of L-
VGCC protein expression and currents might lead to increased cardio-
myocyte contractions, since treatments with other neuropeptides, such
as endothelin-1 and angiotensin-II, have shown such enhancement of
Ca2+-dependent contraction in cardiomyocytes [45–47].
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pertussis toxin (PTX) sensitive G-protein coupled receptors (GPCRs)
might be potential candidates as the receptor for peptide Lv [1].Ra
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Fig. 7. Predicted peptide Lv secondary structure shows potential similarities to the VEGFa and VEGFR2 interaction domains. (A) The schematic structure of the VEGFa dimer (blue and
green) and VEGFR2 (brown and purple) complex (MMDB ID: 96568, PDB ID: 3V2A). (B and C) The interaction domain located in VEGFa is in yellow. The loop region (yellow) in conjunc-
tion with two beta sheets is important for the interaction between VEGFa and VEGFR2. (D and E) The predicted secondary structures of peptide Lv were obtained from the I-TASSER pro-
gram. The C-scores of the predicted structures are−2.30 (D) and−5 (E), respectively. Both predicted structures contain a helix domain and two beta sheets with a loop formed in
between. There are partial similarities among the predicted peptide Lv secondary structure and the VEGFa domain where VEGFa interacts with VEGFR2. (F) The alignment of amino
acid sequences in the loop region shows partial homology between peptide Lv and VEGFa. “*” represents identical amino acids. “:” represents highly conserved substitutions.
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a signaling complex with VEGFR2 and evoke both G-protein coupled
and receptor-tyrosine kinase (RTK) activities [48]. The crosstalk
between GPCRs, G-proteins, and RTKs is critical for endothelial cell
proliferation, migration, and angiogenesis [49,50]. The sphingosine1-
phosphate receptor, a PTX sensitive GPCR, is able to form a complex
with VEGFR2 and evoke G-protein coupled signaling and tyrosine ki-
nase activity [48]. We observed that PTX blocked peptide Lv-induced
augmentation on L-VGCCs and activation of pERK in cardiomyocytes
(Supplemental data) and photoreceptors [1]. However, another GPCR
inhibitor SCH202676, an allosteric modulator with the ability to inhibit
ligand binding to GPCRs [51], did not block the action of peptide Lv
in cardiomyocytes (Supplemental data). Pertussis toxin catalyzes
ADP-ribosylation of G-proteins, thus impairing the interaction between
the receptor and its associated G proteins and inhibits GPCRs [52,53],
while SCH202676 directly blocks the ligand binding sites on GPCRs
[51]. Since SCH202676 did not reverse the action of peptide Lv in
cardiomyocytes (Supplemental data), the activity of peptide Lv mightnot be directly mediated through GPCRs. Nevertheless, we cannot
completely exclude the possibility that peptide Lv might elicit a
crosstalk between G-protein mediated signaling and RTK.
In summary, we demonstrated that peptide Lv interacted with
VEGFR2 and triggered receptor tyrosine kinase activity, as well as the
downstream signaling pathway in cardiomyocytes. Peptide Lv enhanced
Ca2+ entry by increasing L-VGCC currents through increasing the
expression of L-VGCCα1 subunits. The interaction between peptide Lv
and VEGFR2 represents a novel pathway regulating angiogenesis and
cardiac physiology. Further investigation on the dynamic complex of
peptide Lv, VEGFs, VEGFR2, and additional binding partners will be
critical for understanding the physiological function of peptide Lv in
the cardiovascular system.Conﬂict of interest
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